L-methionine decreases dendritic spine density in mouse frontal cortex.
Schizophrenia postmortem brain is characterized by gamma aminobutyric acid downregulation and by decreased dendritic spine density in frontal cortex. Protracted L-methionine treatment exacerbates schizophrenia symptoms, and our earlier work (Tremolizzo et al. and Dong et al.) has shown that L-methionine decreases reelin and GAD67 transcription in mice which is prevented by co-administration of valproate. In this study, we observed a decrease in spine density following L-methionine treatment, which was prevented by co-administration of valproate. Together with our earlier findings conducted under the same experimental conditions, we suggest that downregulation of spine density in L-methionine-treated mice may be because of the decreased expression of reelin and that valproate may prevent spine downregulation by inhibiting the methylation induced decrease in reelin.
Tueting
Patricia
P
Department of Psychiatry, Psychiatric Institute, College of Medicine, University of Illinois at Chicago, USA. ptueting@psych.uic.edu
Davis
John M
JM
Veldic
Marin
M
Pibiri
Fabio
F
Kadriu
Bashkim
B
Guidotti
Alessandro
A
Costa
Erminio
E
D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology / Q000627:therapeutic use; D015816:Cell Adhesion Molecules, Neuronal / Q000187:drug effects / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology; D048430:Cell Shape / Q000187:drug effects / Q000502:physiology; D049229:Dendritic Spines / Q000187:drug effects* / Q000473:pathology*; D004195:Disease Models, Animal; D015536:Down-Regulation / Q000187:drug effects / Q000502:physiology; D004347:Drug Interactions / Q000502:physiology; D016326:Extracellular Matrix Proteins / Q000187:drug effects / Q000378:metabolism; D005625:Frontal Lobe / Q000187:drug effects* / Q000473:pathology* / Q000503:physiopathology; D018682:GABA Agents / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008715:Methionine / Q000378:metabolism / Q000633:toxicity*; D008745:Methylation / Q000187:drug effects; D051379:Mice; D009419:Nerve Tissue Proteins / Q000187:drug effects / Q000378:metabolism; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use; D009498:Neurotoxins / Q000378:metabolism / Q000633:toxicity; D000091042:Reelin Protein; D012559:Schizophrenia / Q000139:chemically induced / Q000473:pathology* / Q000503:physiopathology; D012697:Serine Endopeptidases / Q000187:drug effects / Q000378:metabolism; D013569:Synapses / Q000187:drug effects / Q000473:pathology; D014635:Valproic Acid / Q000494:pharmacology / Q000627:therapeutic use
D000927:Anticonvulsants; D015816:Cell Adhesion Molecules, Neuronal; D016326:Extracellular Matrix Proteins; D018682:GABA Agents; D009419:Nerve Tissue Proteins; D018696:Neuroprotective Agents; D009498:Neurotoxins; D000091042:Reelin Protein; D014635:Valproic Acid; D008715:Methionine; C000717128:Reln protein, mouse; D012697:Serine Endopeptidases